No Data
No Data
Monday Market Mixed Before Crazy, Piovitol Week | Live Stock
Express News | BT Group PLC Morgan Stanley - Holding(S) in Company
Citi: Maintains 'shareholding' rating for Samsonite, target price lowered to 30 Hong Kong dollars.
Morgan Stanley released a research report stating that it has lowered Samsonite (01910) target price by 14.3%, from 35 Hong Kong dollars to 30 Hong Kong dollars, mainly due to the decrease in earnings per share forecast. The rating remains as 'shareholding'. In addition, Samsonite has repurchased 39 million shares since the beginning of the year, with expectations for continued buybacks. Morgan Stanley expects Samsonite's third-quarter 2024 sales and adjusted EBITDA to decrease by 5% and 18%. In the Asia region, China and India may be the main drags. In North America, Morgan Stanley believes that third-quarter sales will be worse than the second quarter. Europe's performance is relatively good, but Morgan Stanley believes that sales growth is still slowing down.
Taimei Medical Technology: stable price action, end of stable price period, and expiration of excess stock subscription rights
NutriMedical Technology (02576) announced that the stabilizing price period for the global offering has ended on November 2, 2024 (Saturday) (i.e. 30 days after the deadline for submitting applications for public offering in Hong Kong). The stabilization operations conducted by Morgan Stanley Asia Limited and its affiliates or any concerted action person during the stabilization price period include: a total of 3.8668 million H shares issued in the international offering, representing approximately 15.00% of the total number of shares available for subscription in the global offering (as disclosed after exercise of the overallotment option but before exercise of any additional share issuance option).
With 62% Ownership of the Shares, Morgan Stanley (NYSE:MS) Is Heavily Dominated by Institutional Owners
Weekly Buzz: Magnificent Mix of Market Reactions